📊 MRK Key Takeaways
Is Merck & Co., Inc. (MRK) a Good Investment?
Merck demonstrates exceptional financial health with industry-leading profitability (28.1% net margin, 34.7% ROE) and robust cash generation ($12.4B FCF). The company maintains a strong balance sheet with solid liquidity (1.54x current ratio) and exceptional interest coverage (69.5x), supporting sustainable operations and shareholder returns despite minimal revenue growth.
Merck shows high-quality profitability with a 32.4% operating margin, 28.1% net margin, 34.7% ROE, and strong interest coverage, indicating an efficient and financially resilient business. Free cash flow of $12.36B and solid liquidity support balance sheet flexibility, while modest 1.3% revenue growth suggests the core business remains stable but not currently in a high-growth phase.
Why Buy Merck & Co., Inc. Stock? MRK Key Strengths
- Outstanding profitability with 28.1% net margin and 32.4% operating margin, significantly above pharma industry averages
- Exceptional return on equity of 34.7% and ROA of 13.3%, demonstrating efficient capital deployment
- Strong free cash flow generation of $12.4B with 19.0% FCF margin, providing flexibility for R&D and shareholder distributions
- Fortress balance sheet with $14.6B cash, manageable 0.89x debt-to-equity ratio, and exceptional 69.5x interest coverage
- Solid liquidity position with 1.54x current ratio and 1.30x quick ratio supporting operational continuity
- Significant insider activity with 26 Form 4 filings in last 90 days suggesting management confidence
- Excellent profitability, with very strong operating and net margins for a large pharmaceutical company
- Healthy financial position, including 1.54x current ratio, 1.30x quick ratio, and 69.5x interest coverage
- Robust cash generation, with $16.47B operating cash flow and $12.36B free cash flow
MRK Stock Risks: Merck & Co., Inc. Investment Risks
- Minimal revenue growth of only 1.3% YoY raises concerns about top-line expansion and pipeline sustainability
- Flat net income growth (0.0% YoY) despite EPS growth of 8.0% suggests earnings driven by share buybacks rather than operational improvement
- High long-term debt of $46.8B represents meaningful leverage, requiring sustained cash flow to service obligations
- Pharmaceutical sector faces persistent patent cliff, pricing pressure, and regulatory risks affecting future revenue stability
- Limited visibility into gross margin trends (N/A in data) restricts analysis of underlying cost structure and pricing power
- Revenue growth is modest at 1.3% YoY, which may limit upside if the product portfolio does not reaccelerate
- Leverage is meaningful, with $46.75B of long-term debt and debt-to-equity of 0.89x
- Pharmaceutical fundamentals can be vulnerable to product concentration, patent expirations, and pipeline execution risk
Key Metrics to Watch
- Revenue growth acceleration - critical to validate pipeline productivity and organic growth sustainability
- Operating cash flow trends - essential to confirm cash generation quality and dividend/buyback sustainability
- R&D spending efficiency and pipeline advancement - measures future competitive positioning in pharmaceutical market
- Debt reduction progress - important given $46.8B obligation and ability to refinance in changing rate environment
- Free cash flow conversion rate - validates profitability quality and capital allocation discipline
- Revenue growth and diluted EPS growth
- Free cash flow generation and debt levels
Merck & Co., Inc. (MRK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Merck & Co., Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MRK Profit Margin, ROE & Profitability Analysis
MRK vs Healthcare Sector: How Merck & Co., Inc. Compares
How Merck & Co., Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Merck & Co., Inc. Stock Overvalued? MRK Valuation Analysis 2026
Based on fundamental analysis, Merck & Co., Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Merck & Co., Inc. Balance Sheet: MRK Debt, Cash & Liquidity
MRK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Merck & Co., Inc.'s revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.14 reflects profitable operations.
MRK Revenue Growth, EPS Growth & YoY Performance
MRK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $16.7B | $3.2B | $1.24 |
| Q2 2025 | $15.8B | $4.4B | $1.76 |
| Q1 2025 | $15.5B | $4.8B | $1.87 |
| Q3 2024 | $16.0B | $1.6B | $0.62 |
| Q2 2024 | $15.0B | -$3.2B | $-1.24 |
| Q1 2024 | $14.5B | $2.8B | $1.11 |
| Q3 2023 | $15.0B | $1.6B | $0.62 |
| Q2 2023 | $14.6B | -$3.2B | $-1.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Merck & Co., Inc. Dividends, Buybacks & Capital Allocation
MRK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Merck & Co., Inc. (CIK: 0000310158)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRK
What is the AI rating for MRK?
Merck & Co., Inc. (MRK) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRK's key strengths?
Claude: Outstanding profitability with 28.1% net margin and 32.4% operating margin, significantly above pharma industry averages. Exceptional return on equity of 34.7% and ROA of 13.3%, demonstrating efficient capital deployment. ChatGPT: Excellent profitability, with very strong operating and net margins for a large pharmaceutical company. Healthy financial position, including 1.54x current ratio, 1.30x quick ratio, and 69.5x interest coverage.
What are the risks of investing in MRK?
Claude: Minimal revenue growth of only 1.3% YoY raises concerns about top-line expansion and pipeline sustainability. Flat net income growth (0.0% YoY) despite EPS growth of 8.0% suggests earnings driven by share buybacks rather than operational improvement. ChatGPT: Revenue growth is modest at 1.3% YoY, which may limit upside if the product portfolio does not reaccelerate. Leverage is meaningful, with $46.75B of long-term debt and debt-to-equity of 0.89x.
What is MRK's revenue and growth?
Merck & Co., Inc. reported revenue of $65.0B.
Does MRK pay dividends?
Merck & Co., Inc. pays dividends, with $8,176.0M distributed to shareholders in the trailing twelve months.
Where can I find MRK SEC filings?
Official SEC filings for Merck & Co., Inc. (CIK: 0000310158) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRK's EPS?
Merck & Co., Inc. has a diluted EPS of $7.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Merck & Co., Inc. has a BUY rating with 80% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is MRK stock overvalued or undervalued?
Valuation metrics for MRK: ROE of 34.7% (sector avg: 15%), net margin of 28.1% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy MRK stock in 2026?
Our dual AI analysis gives Merck & Co., Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is MRK's free cash flow?
Merck & Co., Inc.'s operating cash flow is $16.5B, with capital expenditures of $4.1B. FCF margin is 19.0%.
How does MRK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 28.1% (avg: 12%), ROE 34.7% (avg: 15%), current ratio 1.54 (avg: 2).
Why is MRK's return on equity (ROE) so high?
Merck & Co., Inc. has a return on equity of 34.7%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 28.1% net margin.